Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC – Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 17,259 shares. Based on an average daily volume of 112,857 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are short sold.
Insider Buying and Selling
In other news, CEO Albert Cha bought 300,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the chief executive officer owned 300,000 shares in the company, valued at approximately $3,000,000. This represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Frazier Life Sciences Acquisition Corp. II Price Performance
Shares of FLSC traded down $0.04 during mid-day trading on Friday, hitting $10.17. 3,763 shares of the company traded hands, compared to its average volume of 141,373. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.10 and a 1 year high of $10.63.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research note on Saturday, October 24th.
Get Our Latest Stock Analysis on FLSC
About Frazier Life Sciences Acquisition Corp. II
Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.
Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.
Frazier Life Sciences Acquisition Corp.
See Also
- Five stocks we like better than Frazier Life Sciences Acquisition Corp. II
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Frazier Life Sciences Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Life Sciences Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.
